We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+17.25%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.31B
AUM Growth
-$35.5M
Cap. Flow
-$36M
Cap. Flow %
-2.75%
Top 10 Hldgs %
77.05%
Holding
40
New
3
Increased
8
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$25.2M
2
WGS icon
GeneDx Holdings
WGS
+$7.39M
3
RLAY icon
Relay Therapeutics
RLAY
+$7M
4
KYTX icon
Kyverna Therapeutics
KYTX
+$6.49M
5
IPSC icon
Century Therapeutics
IPSC
+$6.27M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$45.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$17.1M
4
ABCL icon
AbCellera Biologics
ABCL
+$10.7M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTNM
26
Contineum Therapeutics
CTNM
$599M
$5.22M 0.4%
+296,666
New +$4.78M
KYTX icon
27
Kyverna Therapeutics
KYTX
$457M
$4.31M 0.33%
575,000
+425,000
+283% +$6.49M
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.7B
$3.08M 0.24%
150,000
– –
ABSI icon
29
Absci
ABSI
$1.34B
$3M 0.23%
973,260
– –
GH icon
30
Guardant Health
GH
$21.3B
$2.89M 0.22%
+100,000
New +$2.33M
PRME icon
31
Prime Medicine
PRME
$508M
$1.89M 0.14%
367,175
– –
PACB icon
32
Pacific Biosciences
PACB
$441M
$1.42M 0.11%
1,035,859
– –
GRAL
33
GRAIL Inc
GRAL
$3.02B
$1.23M 0.09%
+79,999
New +$1.3M
EXAI
34
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.09M 0.08%
213,900
– –
GLUE icon
35
Monte Rosa Therapeutics
GLUE
$1.3B
$976K 0.07%
261,014
-249,868
-49% -$1.27M
DNA icon
36
Ginkgo Bioworks
DNA
$584M
$488K 0.04%
36,494
– –
OMIC
37
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$373K 0.03%
44,129
-1
-0% -$12
KRON
38
DELISTED
Kronos Bio
KRON
$154K 0.01%
123,839
– –
ABCL icon
39
AbCellera Biologics
ABCL
$1.78B
– –
-2,360,129
Closed -$10.7M
NTLA icon
40
CALL
Intellia Therapeutics
NTLA
$1.5B
– –
-50,000
Closed -$1.38M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Casdin Capital held 40 positions worth $1.31B, down 2.6% from $1.35B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Casdin Capital's Q2 2024 filing shows 3 new, 8 increased, 5 reduced and 2 closed positions. Its largest new stake was Contineum Therapeutics: 296,666 shares worth $5.22M. The largest sale was Revolution Medicines, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Casdin Capital's largest Q2 2024 buy was Contineum Therapeutics: 296,666 shares worth $5.22M.
  • Casdin Capital added most to Illumina in Q2 2024, an estimated $25.2M increase.
  • Casdin Capital's biggest Q2 2024 reduction was Revolution Medicines, cutting an estimated $45.3M.
  • Casdin Capital fully exited AbCellera Biologics in Q2 2024, selling an estimated $10.7M.
  • Casdin Capital's ten largest holdings make up 77% of its $1.31B portfolio in Q2 2024.
  • Casdin Capital opened 3 new positions and closed 2 in Q2 2024.
  • Casdin Capital's portfolio value fell 2.6% quarter-over-quarter to $1.31B.

Based on Casdin Capital's 13F filing for Q2 2024, filed 14 Aug 2024.